Skip to Content

Miglitol Disease Interactions

There are 3 disease interactions with miglitol:

Major

Alpha-Glucosidase Inhibitors (Includes Miglitol) ↔ Diabetic Ketoacidosis

Severe Potential Hazard, Moderate plausibility

Applies to: Diabetic Ketoacidosis

The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.

Major

Alpha-Glucosidase Inhibitors (Includes Miglitol) ↔ Intestinal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Colonic Ulceration, Intestinal Obstruction, Malabsorption Syndrome, Colitis/Enteritis (Noninfectious)

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

References

  1. Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
  2. "Product Information. Glyset (miglitol)." Bayer, West Haven, CT.
  3. Nishii Y, Aizawa T, Hashizume K "Ileus: a rare side effect of acarbose." Diabetes Care 19 (1996): 1033
  4. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  5. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
View all 5 references
Major

Miglitol (Includes Miglitol) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Miglitol is eliminated primarily by the kidney. Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with miglitol should be administered cautiously in patients with renal insufficiency. The manufacturer does not recommend its use in patients with significantly impaired renal function.

References

  1. "Product Information. Glyset (miglitol)." Bayer, West Haven, CT.

miglitol drug Interactions

There are 652 drug interactions with miglitol

miglitol alcohol/food Interactions

There is 1 alcohol/food interaction with miglitol

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide